ES3060114T3 - - Google Patents

Info

Publication number
ES3060114T3
ES3060114T3 ES19855537T ES19855537T ES3060114T3 ES 3060114 T3 ES3060114 T3 ES 3060114T3 ES 19855537 T ES19855537 T ES 19855537T ES 19855537 T ES19855537 T ES 19855537T ES 3060114 T3 ES3060114 T3 ES 3060114T3
Authority
ES
Spain
Prior art keywords
pharmaceutically acceptable
acceptable salts
clarithromycin
amoxicillin
helicobacter pylori
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19855537T
Other languages
English (en)
Spanish (es)
Inventor
Bong Tae Kim
Dongkyu Kim
Eun Ji Kim
Ji Won Lee
Kyeongmin Oh
Ahrong Kim
Geun Seog Song
Shin-Young Ryu
Eun Kyung Kim
Naree Shin
Hyun Ji Kang
Jae Min Kim
Yu-Gyeong Park
Haneul Jeong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HK Inno N Corp
Original Assignee
HK Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HK Inno N Corp filed Critical HK Inno N Corp
Application granted granted Critical
Publication of ES3060114T3 publication Critical patent/ES3060114T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES19855537T 2018-08-29 2019-08-28 Active ES3060114T3 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180102250 2018-08-29
PCT/KR2019/011017 WO2020045992A1 (en) 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori

Publications (1)

Publication Number Publication Date
ES3060114T3 true ES3060114T3 (https=) 2026-03-25

Family

ID=69643254

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19855537T Active ES3060114T3 (https=) 2018-08-29 2019-08-28

Country Status (25)

Country Link
US (2) US20210196685A1 (https=)
EP (1) EP3843723B1 (https=)
JP (1) JP7189327B2 (https=)
KR (1) KR20200026118A (https=)
CN (1) CN112638378A (https=)
AR (1) AR116026A1 (https=)
AU (1) AU2019328903B2 (https=)
CA (1) CA3107624C (https=)
DK (1) DK3843723T3 (https=)
EA (1) EA202190622A1 (https=)
ES (1) ES3060114T3 (https=)
FI (1) FI3843723T3 (https=)
GE (2) GEP20227431B (https=)
JO (1) JOP20190201B1 (https=)
LT (1) LT3843723T (https=)
MX (1) MX2021002278A (https=)
MY (1) MY195494A (https=)
PH (1) PH12021550385A1 (https=)
PT (1) PT3843723T (https=)
RS (1) RS67791B1 (https=)
SG (1) SG11202101920WA (https=)
SI (1) SI3843723T1 (https=)
UA (1) UA126993C2 (https=)
UY (1) UY38348A (https=)
WO (1) WO2020045992A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3132575A1 (en) * 2019-04-18 2020-10-22 Thomas Julius Borody Compositions and methods for treating, ameliorating and preventing h. pylori infections
WO2024210689A1 (ko) * 2023-04-07 2024-10-10 제이더블유중외제약 주식회사 벤즈이미다졸 유도체의 염
TW202535382A (zh) * 2023-11-29 2025-09-16 南韓商第一藥品股份有限公司 包含ｚａｓｔａｐｒａｚａｎ或其醫藥上可接受的鹽之用於幽門螺旋桿菌根除的組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
KR101088247B1 (ko) * 2005-12-19 2011-11-30 라퀄리아 파마 인코포레이티드 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도
CN101015694A (zh) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 一种治疗幽门螺旋杆菌感染的复方口服制剂
HUE056322T2 (hu) * 2015-06-08 2022-02-28 Hk Inno N Corp Benzimidazol-származék alkalmazásai éjszakai savvisszaáramláshoz
WO2017125912A1 (en) * 2016-01-21 2017-07-27 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
CN108379258B (zh) * 2017-11-30 2020-02-18 中国医学科学院医药生物技术研究所 瑞香素在抗幽门螺杆菌中的应用

Also Published As

Publication number Publication date
EP3843723A1 (en) 2021-07-07
UY38348A (es) 2020-03-31
KR20200026118A (ko) 2020-03-10
SG11202101920WA (en) 2021-04-29
MX2021002278A (es) 2021-08-11
WO2020045992A1 (en) 2020-03-05
CA3107624C (en) 2023-10-03
BR112021003578A2 (pt) 2021-05-18
AU2019328903A1 (en) 2021-04-29
CN112638378A (zh) 2021-04-09
DK3843723T3 (da) 2026-02-09
GEP20227431B (en) 2022-10-25
LT3843723T (lt) 2026-03-25
EP3843723A4 (en) 2022-06-29
AU2019328903A8 (en) 2021-05-27
UA126993C2 (uk) 2023-03-01
PH12021550385A1 (en) 2021-09-20
CA3107624A1 (en) 2020-03-05
MY195494A (en) 2023-01-26
JOP20190201A1 (ar) 2020-02-29
US20250241897A1 (en) 2025-07-31
JP2021535910A (ja) 2021-12-23
AR116026A1 (es) 2021-03-25
US20210196685A1 (en) 2021-07-01
PT3843723T (pt) 2026-01-27
EP3843723B1 (en) 2026-01-07
FI3843723T3 (fi) 2026-02-12
JP7189327B2 (ja) 2022-12-13
JOP20190201B1 (ar) 2024-04-18
GEAP202215593A (en) 2022-07-11
EA202190622A1 (ru) 2021-06-10
SI3843723T1 (sl) 2026-04-30
AU2019328903B2 (en) 2023-01-05
RS67791B1 (sr) 2026-03-31

Similar Documents

Publication Publication Date Title
ES3060114T3 (https=)
de Boer et al. Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study
US11033532B2 (en) Uses of benzimidazole derivative for nocturnal acid breakthrough
US11938123B2 (en) Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers
JP2013227350A (ja) 放射線直腸ｓ状結腸炎を処置するための組成物および方法
KR20250090275A (ko) 벤즈이미다졸 유도체 화합물을 포함하는 약학적 조성물
CN101534840A (zh) 治疗放射性肠炎的方法
ES2963784T3 (es) Uso de delgocitinib para el tratamiento del eccema crónico de manos
WO2016120787A1 (en) Oral n-acetylcysteine in the treatment of upper respiratory tract infections and symptoms
CN111163762A (zh) 组合物在预防和/或治疗肿瘤治疗诱发的口腔和胃肠粘膜炎中的用途
EA043853B1 (ru) Композиция для эрадикации helicobacter pylori
BR112021003578B1 (pt) Composição e método para erradicar helicobacter pylori
JP2007091761A (ja) Ｈ．ｐｙｌｏｒｉに起因する胃腸障害の処置のためのスピラマイシン含有薬剤
KR20230027226A (ko) 화학요법-유발 설사를 치료하기 위한 방법 및 조성물
TWI676477B (zh) 苯并咪唑衍生物用於夜間酸突破的用途
RU2214819C1 (ru) Упаковка лекарственных средств для лечения или предотвращения желудочно-кишечных заболеваний, вызываемых или опосредуемых заражением helicobacter pylori
JP2025538641A (ja) ザスタプラザンまたはこの薬剤学的に許容される塩を含むヘリコバクター・ピロリ除菌用組成物
WO2025103426A1 (zh) 白塞综合征的治疗
Soe et al. The Efficacy of Concomitant Vs Clarithromycin Based Triple Therapy in Helicobacter Pylori Infected Peptic Ulcer Patients
JP2006045200A (ja) 間質性膀胱炎の治療薬
Monnerat et al. Mucositis: Centre Hospitalier Universitaire Vaudois, Suisse
MXPA06014635A (es) Composicion farmaceutica que contiene una combinacion de antibiotico y mucolitico y su uso.
MXPA96004986A (es) Utilizacion de espiramicina en transtornos gastrointestinales causados por h. pylori